APA (7th ed.) Citation

Bartlett, N. L., Yasenchak, C. A., Sims, R. B., & Nowakowski, G. S. (2020). Trial-in-Progress: Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 136(Supplement 1), 14. https://doi.org/10.1182/blood-2020-136400

Chicago Style (17th ed.) Citation

Bartlett, Nancy L., Christopher A. Yasenchak, Robert B. Sims, and Grzegorz S. Nowakowski. "Trial-in-Progress: Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)." Blood 136, no. Supplement 1 (2020): 14. https://doi.org/10.1182/blood-2020-136400.

MLA (9th ed.) Citation

Bartlett, Nancy L., et al. "Trial-in-Progress: Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)." Blood, vol. 136, no. Supplement 1, 2020, p. 14, https://doi.org/10.1182/blood-2020-136400.